Published in Cancer Cell on April 12, 2011
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell (2014) 3.08
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature (2015) 1.99
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst (2013) 1.75
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med (2012) 1.10
Advances in the treatment of chronic myeloid leukemia. BMC Med (2011) 1.05
NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A (2013) 1.03
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma (2012) 1.01
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol (2014) 1.00
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood (2011) 0.98
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br J Pharmacol (2012) 0.97
Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS One (2012) 0.96
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res (2012) 0.95
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res (2013) 0.94
Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clin Med Insights Oncol (2011) 0.93
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. PLoS One (2013) 0.91
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell (2013) 0.90
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther (2016) 0.88
Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia (2012) 0.88
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorg Med Chem Lett (2013) 0.87
Development of an effective therapy for chronic myelogenous leukemia. Cancer J (2011) 0.87
Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep (2013) 0.85
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin. Mol Cancer (2014) 0.84
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol (2013) 0.82
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest (2016) 0.81
The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One (2013) 0.80
Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS Chem Biol (2013) 0.80
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov (2016) 0.79
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib. Theranostics (2016) 0.79
Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep (2014) 0.78
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. Adv Hematol (2011) 0.77
Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance. Chem Biol Drug Des (2013) 0.77
Structural interrogation of phosphoproteome identified by mass spectrometry reveals allowed and disallowed regions of phosphoconformation. BMC Struct Biol (2014) 0.76
Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia. Cancer Cell (2011) 0.76
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. Oncotarget (2016) 0.76
Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. J Mol Graph Model (2015) 0.76
Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16. Biochem J (2017) 0.75
Leukaemia: Now get out of that... Nat Rev Cancer (2011) 0.75
Dual function of TGFβ in lens epithelial cell fate: implications for secondary cataract. Mol Biol Cell (2017) 0.75
The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. Oncotarget (2017) 0.75
A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken. Curr Med Chem (2011) 0.75
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep (2015) 0.75
A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors. Org Biomol Chem (2015) 0.75
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol (2011) 0.75
Chronic myeloid leukemia: In pursuit of perfection. South Asian J Cancer (2012) 0.75
Anticancer drugs: Now get out of that.... Nat Rev Drug Discov (2011) 0.75
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment. Biomark Insights (2016) 0.75
CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia. J Cancer (2017) 0.75
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
The conformational plasticity of protein kinases. Cell (2002) 11.21
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem (2000) 8.76
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 5.71
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A (2006) 4.09
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A (2006) 3.48
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature (1996) 2.94
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res (2006) 2.72
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2006) 2.50
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13
Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev (2003) 2.02
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res (2006) 1.98
Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol (2005) 1.67
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res (2007) 1.42
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood (1995) 1.15
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol (2009) 0.99
The developmental transcriptome of Drosophila melanogaster. Nature (2010) 11.85
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 6.24
Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem (2006) 5.92
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
The price of freedom. Cranio (2011) 3.85
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature (2003) 3.77
Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog (2010) 3.65
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer (2007) 3.32
DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2010) 3.00
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med (2013) 2.48
Diversity and dynamics of the Drosophila transcriptome. Nature (2014) 2.47
Spermatozoal RNA profiles of normal fertile men. Lancet (2002) 2.46
The effect of sperm DNA fragmentation on miscarriage rates: a systematic review and meta-analysis. Hum Reprod (2012) 2.46
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One (2006) 2.42
Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42
A de novo mutation in the β-tubulin gene TUBB4A results in the leukoencephalopathy hypomyelination with atrophy of the basal ganglia and cerebellum. Am J Hum Genet (2013) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
A divergent external loop confers antagonistic activity on floral regulators FT and TFL1. EMBO J (2006) 2.29
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci U S A (2002) 2.19
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13
Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology (2003) 2.01
Implications of climate change for agricultural productivity in the early twenty-first century. Philos Trans R Soc Lond B Biol Sci (2010) 1.98
Relationships of Indoor, Outdoor, and Personal Air (RIOPA). Part I. Collection methods and descriptive analyses. Res Rep Health Eff Inst (2005) 1.95
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol (2009) 1.91
The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging (2009) 1.86
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta Obstet Gynecol Scand (2010) 1.80
Neural basis for generalized quantifier comprehension. Neuropsychologia (2005) 1.79
Endonuclease-sensitive regions of human spermatozoal chromatin are highly enriched in promoter and CTCF binding sequences. Genome Res (2009) 1.79
Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
A field investigation of Bacillus anthracis contamination of U.S. Department of Agriculture and other Washington, D.C., buildings during the anthrax attack of October 2001. Appl Environ Microbiol (2003) 1.76
Reproductive biology: delivering spermatozoan RNA to the oocyte. Nature (2004) 1.76
Barbershops as hypertension detection, referral, and follow-up centers for black men. Hypertension (2007) 1.74
The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J Infect Dis (2009) 1.74
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology (2008) 1.66
Understanding the accommodating intraocular lens. J Cataract Refract Surg (2003) 1.63
Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet (2012) 1.60
Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol (2009) 1.56
Impact and recognition of cognitive impairment among hospitalized elders. J Hosp Med (2010) 1.56
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/β-TCP): an alternative to autogenous bone graft. J Bone Joint Surg Am (2013) 1.54
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res (2011) 1.53
Genome wide identification of promoter binding sites for H4K12ac in human sperm and its relevance for early embryonic development. Epigenetics (2012) 1.53
Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell (2004) 1.52
Polycyclic aromatic hydrocarbons in the indoor and outdoor air of three cities in the U.S. Environ Sci Technol (2002) 1.51
Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord (2010) 1.50
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity. Am J Hum Genet (2013) 1.46
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J (2002) 1.45
Neurologists warn about link between chiropractic, stroke. CMAJ (2002) 1.45
Green space and stress: evidence from cortisol measures in deprived urban communities. Int J Environ Res Public Health (2013) 1.44
The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv (2012) 1.44
Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell (2003) 1.43
Influence of ambient (outdoor) sources on residential indoor and personal PM2.5 concentrations: analyses of RIOPA data. J Expo Anal Environ Epidemiol (2005) 1.42
A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol (2009) 1.41
Fear of statins? CMAJ (2009) 1.39
Airborne endotoxin is associated with respiratory illness in the first 2 years of life. Environ Health Perspect (2006) 1.38
Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci (2008) 1.38
Amiodarone rescue therapy for severe decompensated heart failure initially unsuitable for beta-blockers. J Cardiovasc Pharmacol Ther (2003) 1.38
Indicators of perceived naturalness as drivers of landscape preference. J Environ Manage (2008) 1.38
High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci (2005) 1.35
Factors associated with hypertension awareness, treatment, and control in Dallas County, Texas. Arch Intern Med (2008) 1.35
Update on best practice recommendations for anesthetic perioperative care and pain management in weight loss surgery, 2004-2007. Obesity (Silver Spring) (2009) 1.35
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Refined genotype-phenotype correlations in cases of chromosome 6p deletion syndromes. Eur J Hum Genet (2004) 1.31
High-throughput crystallization and structure determination in drug discovery. Drug Discov Today (2002) 1.30
Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci U S A (2012) 1.28
Imported Lassa fever, Pennsylvania, USA, 2010. Emerg Infect Dis (2010) 1.28
Structural genomics of infectious disease drug targets: the SSGCID. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 1.27
Paternal contributions: new functional insights for spermatozoal RNA. J Cell Biochem (2008) 1.27
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther (2011) 1.25
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan assays on the Roche LightCycler. Lab Invest (2004) 1.23
RAD51C interacts with RAD51B and is central to a larger protein complex in vivo exclusive of RAD51. J Biol Chem (2001) 1.23
Differences in "bottom-up" and "top-down" neural activity in current and former cigarette smokers: Evidence for neural substrates which may promote nicotine abstinence through increased cognitive control. Neuroimage (2011) 1.23
SAD phasing using iodide ions in a high-throughput structural genomics environment. J Struct Funct Genomics (2011) 1.23
Tuning the pK(a) of fluorescein to optimize binding assays. Anal Chem (2007) 1.22
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther (2008) 1.22
Combining functional and structural genomics to sample the essential Burkholderia structome. PLoS One (2013) 1.21
Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A (2014) 1.20
Multipolymer solution-phase reactions: application to the Mitsunobu reaction. J Am Chem Soc (2005) 1.20
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms. J Addict Res Ther (2012) 1.19
Natalizumab: bench to bedside and beyond. JAMA Neurol (2013) 1.19